Centre Of Research Excellence In Asthma Treatable Traits (CREATT)
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
This CRE will focus on personalised medicine in asthma, specifically using the treatable traits approach. We have identified disease management areas of highest importance to people with asthma and health care providers. We will generate new knowledge, develop and strengthen collaborations and train translation focused researchers to develop high quality evidence and translate this to practice.
This project will take robust evidence regarding inflammation based management, comorbidity and self management and translate it into practice using a national implementation framework.
National Clinical Centre Of Research Excellence In Severe Asthma
Funder
National Health and Medical Research Council
Funding Amount
$2,597,952.00
Summary
Severe Asthma remains a large burden for the Australian community. It does not respond to current management approaches. We will develop and implement a targetted therapy approach to severe asthma that will involve assessment of needs of people with severe asthma, community burden form severe asthma, biomarkers and linked treatment strategies, as well as knowledge transfer tools and training of the health and medical workforce.
Role Of Toll-like Receptor 7 In Rhinovirus-induced Asthma Exacerbation
Funder
National Health and Medical Research Council
Funding Amount
$697,248.00
Summary
One third of the annual asthma-related health care expenditure may be attributable to asthma-related hospitalisations. Even mild asthmatics experience severe exacerbations at a rate of almost one per year1 and those attacks can be fatal. Rhinovirus (RV) causes the majority of asthma exacerbations which may be linked to an impaired antiviral interferon (IFN) response in asthmatics. RV is sensed by Toll-like receptor (TLR) 7, but the role of this innate host defence pathway in regulating antiviral
Optimising Asthma Management In Pregnancy For Optimal Infant Health
Funder
National Health and Medical Research Council
Funding Amount
$428,065.00
Summary
Asthma affects 12% of pregnant women in Australia. These women are at increased risk of poor pregnancy outcomes, such as preterm birth and hospitalisation of the neonate. Reducing asthma attacks by providing optimal asthma management during pregnancy may lower these risks. This research will test whether a strategy which determines treatment changes based on a marker of airway inflammation, improves outcomes for maternal, neonatal and child health.
Anti-viral Immune Dysfunction In Severe Asthma Varies Across Inflammatory Phenotypes.
Funder
National Health and Medical Research Council
Funding Amount
$997,153.00
Summary
Common cold viruses often trigger asthma flare-ups , but have relatively minor effects on healthy people. Why this happens is not clear. We have identified two different ways in which the immune system can react badly to a common cold virus in people with asthma. In this study we will find out more about why the immune system does not react normally in a large group of people with severe asthma. This study will help us discover improved treatments that can be targeted to people with asthma.
Viral Infection And TGFbeta Impair Glucocorticoid Activity In Epithelial Cells
Funder
National Health and Medical Research Council
Funding Amount
$617,699.00
Summary
Chronic inflammatory lung diseases like asthma and smokers lung are treated with combinations of anti-inflammatory drugs. Powerful anti-inflammatory types of steroid drugs are used in more severe disease. Even these powerful drugs are sometimes not effective enough. Our work is developing an understanding of how inflammation limits the anti-inflammatory effects of steroids and we are devising ways to overcome this with new drugs. We aim to improve treatment of chronic inflammatory diseases, espe ....Chronic inflammatory lung diseases like asthma and smokers lung are treated with combinations of anti-inflammatory drugs. Powerful anti-inflammatory types of steroid drugs are used in more severe disease. Even these powerful drugs are sometimes not effective enough. Our work is developing an understanding of how inflammation limits the anti-inflammatory effects of steroids and we are devising ways to overcome this with new drugs. We aim to improve treatment of chronic inflammatory diseases, especially those affecting the lung.Read moreRead less
Targeting Translational Control By Modulating MiRNA Function As A Novel Way To Treat Respiratory Infections And Inflammatory Disease
Funder
National Health and Medical Research Council
Funding Amount
$700,623.00
Summary
Among the major health issues of today is our inability to effectively treat bacterial infections and the emergence of antibiotic resistant microbes. MicroRNA are small molecules that control the levels of proteins in immune cells that fight infections. In this project we will determine if inhibiting miRNA function in the lung enhances defence against microbial invasion and is a new therapeutic approach to treat infection driven diseases of the airways such asthma and emphysema.
Understanding How Azithromycin Prevents Exacerbations In Severe Asthma
Funder
National Health and Medical Research Council
Funding Amount
$697,273.00
Summary
In some people with severe asthma, conventional inhaler treatments are not able to control the disease so there is a need for new treatment options. We have recently completed a large clinical trial which showed that very low doses of a common antibiotic help prevent asthma attacks in this situation. However, not much is known about how the antibiotic is working. This study will help us understand how the antibiotic is working and which people respond best.
Rhinovirus Protease Subcellular Trafficking And Host Cell Targets; Relevance To Asthma Exacerbation And Vaccine Approaches
Funder
National Health and Medical Research Council
Funding Amount
$582,072.00
Summary
Rhinovirus (RV) infections are the major cause of virus induced asthma attacks, causing significant morbidity and mortality. Asthma & asthma exacerbations are increasing worldwide with new strategies urgently needed to reduce RV-associated disease. We aim to build on our substantive new data, using cutting edge technology to identify new targets for novel asthma therapies.